{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:14:24Z","timestamp":1771661664167,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Polypharmacy is a frequent situation in older adults that increases the risk of drug-drug interactions (DDIs), both pharmacokinetic (PK) and pharmacodynamic (PD). Direct oral anticoagulants (DOACs) are frequently prescribed in older adults, mainly because of the high prevalence of atrial fibrillation (AF). DOACs are subject to cytochrome P450 3A4 (CYP3A4)- and\/or P-glycoprotein (P-gp)-mediated PK DDIs and PD DDIs when co-administered with drugs that interfere with platelet function. The aim of our study was to assess the prevalence of DDIs involving DOACs in older adults and the associated risk factors at admission and discharge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a cross-sectional study conducted in an acute geriatric unit between January 1, 2018 and December 31, 2022, including patients over 75 years of age treated with DOACs at admission and\/or discharge, for whom a comprehensive collection of co-medications was performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From 909 hospitalizations collected, the prevalence of PK DDIs involving DOACs was 16.9% at admission and 20.7% at discharge, and the prevalence of PD DDIs was 20.7% at admission and 20.2% at discharge. Factors associated with DDIs were bleeding history [adjusted odds ratio (ORa) 1.74, 95% confidence interval (CI) 1.13\u20132.68], number of drugs\u2009&gt;\u20096 (ORa 2.54, 95% CI 1.88\u20133.46) and reduced dose of DOACs (ORa 0.39, 95% CI 0.28\u20130.54) at admission and age\u2009&gt;\u200987 years (ORa 0.74, 95% CI 0.55\u20130.99), number of drugs\u2009&gt;\u20096 (ORa 2.01, 95% CI 1.48\u20132.72) and reduced dose of DOACs (ORa 0.41, 95% CI 0.30\u20130.57) at discharge.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study provides an indication of the prevalence of DDIs as well as the profile of DDIs and patients treated with DOACs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40520-024-02768-w","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T05:01:40Z","timestamp":1716354100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics and pharmacodynamics of drug\u2012drug interactions in hospitalized older adults treated with direct oral anticoagulants"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0142-0210","authenticated-orcid":false,"given":"Th\u00e9odore","family":"Decaix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenza","family":"Kemache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Gay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Ketz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Lapr\u00e9vote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9ric","family":"Pautas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"2768_CR1","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf 17:1185\u20131196. https:\/\/doi.org\/10.1080\/14740338.2018.1546841","journal-title":"Expert Opin Drug Saf"},{"key":"2768_CR2","doi-asserted-by":"publisher","first-page":"CD008165","DOI":"10.1002\/14651858.CD008165.pub4","volume":"9","author":"A Rankin","year":"2018","unstructured":"Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC et al (2018) Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 9:CD008165. https:\/\/doi.org\/10.1002\/14651858.CD008165.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"2768_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0749-0690(18)30503-2","volume":"8","author":"SC Montamat","year":"1992","unstructured":"Montamat SC, Cusack B (1992) Overcoming problems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med 8:143\u2013158","journal-title":"Clin Geriatr Med"},{"key":"2768_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"C Marzolini","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13\u201333. https:\/\/doi.org\/10.1016\/j.clpt.2003.09.012","journal-title":"Clin Pharmacol Ther"},{"key":"2768_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"2768_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejim.2019.05.002","volume":"65","author":"P Gallo","year":"2019","unstructured":"Gallo P, De Vincentis A, Pedone C, Nobili A, Tettamanti M, Gentilucci UV et al (2019) REPOSI investigators. Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. Eur J Intern Med 65:51\u201357. https:\/\/doi.org\/10.1016\/j.ejim.2019.05.002","journal-title":"Eur J Intern Med"},{"key":"2768_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ et al (2014) Worldwide epidemiology of atrial fibrillation: a global burden of Disease 2010 study. Circulation 129:837\u2013847. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"2768_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jamacardio.2016.1829","volume":"1","author":"JH Alexander","year":"2016","unstructured":"Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA et al (2016) ARISTOTLE investigators. Apixaban 5\u00a0mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. JAMA Cardiol 1:673\u2013681. https:\/\/doi.org\/10.1001\/jamacardio.2016.1829","journal-title":"JAMA Cardiol"},{"issue":"08","key":"2768_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/jcph.288","volume":"54","author":"IG Girgis","year":"2014","unstructured":"Girgis IG, Patel MR, Peters GR, Moore KT, Mahaffey KW, Nessel CC et al (2014) Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol 54(08):917\u2013927. https:\/\/doi.org\/10.1002\/jcph.288","journal-title":"J Clin Pharmacol"},{"key":"2768_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-9560-11-10","volume":"11","author":"W Mueck","year":"2013","unstructured":"Mueck W, Schwers S, Stampfuss J (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 11:1. https:\/\/doi.org\/10.1186\/1477-9560-11-10","journal-title":"Thromb J"},{"key":"2768_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/jcph.5","volume":"53","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Becka M, Roth A, Mueck W (2013) The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor xa inhibitor. J Clin Pharmacol 53:249\u2013225. https:\/\/doi.org\/10.1002\/jcph.5","journal-title":"J Clin Pharmacol"},{"key":"2768_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1080\/17425255.2016.1225037","volume":"12","author":"C Voukalis","year":"2016","unstructured":"Voukalis C, Lip GY, Shantsila E (2016) Drug-drug interactions of non-vitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol 12:1445\u20131461. https:\/\/doi.org\/10.1080\/17425255.2016.1225037","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2768_CR13","doi-asserted-by":"publisher","unstructured":"Li A, Li MK, Crowther M, Vazquez SR (2020) Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb Res. 194:240\u2013245. https:\/\/doi.org\/10.1016\/j.thromres.","DOI":"10.1016\/j.thromres"},{"key":"2768_CR14","doi-asserted-by":"publisher","unstructured":"Li A, Li MK, Crowther M, Vazquez SR (2020) Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb Res. 194:240\u2013245. https:\/\/doi.org\/10.1016\/j.thromres.","DOI":"10.1016\/j.thromres"},{"key":"2768_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","volume":"110","author":"N Gronich","year":"2021","unstructured":"Gronich N, Stein N, Muszkat M (2021) Association between Use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study. Clin Pharmacol Ther 110:1526\u20131536. https:\/\/doi.org\/10.1002\/cpt.2369","journal-title":"Clin Pharmacol Ther"},{"key":"2768_CR16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/cpt.2714","volume":"113","author":"LE Thompson","year":"2023","unstructured":"Thompson LE, Davis BH, Narayan R, Goff B, Brown TM, Limdi NA (2023) Personalizing direct oral anticoagulant therapy for a Diverse Population: role of race, kidney function, drug interactions, and Pharmacogenetics. Clin Pharmacol Ther 113:585\u2013599. https:\/\/doi.org\/10.1002\/cpt.2714","journal-title":"Clin Pharmacol Ther"},{"key":"2768_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2021.09.025","volume":"162","author":"D Sanborn","year":"2022","unstructured":"Sanborn D, Sugrue A, Amin M, Mehta R, Farwati M, Deshmukh AJ et al (2022) Outcomes of direct oral anticoagulants co-prescribed with common interacting medications. Am J Cardiol 162:80\u201385. https:\/\/doi.org\/10.1016\/j.amjcard.2021.09.025","journal-title":"Am J Cardiol"},{"key":"2768_CR18","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of Anticoagulation (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119\u20132126. https:\/\/doi.org\/10.1111\/jth.13140","journal-title":"J Thromb Haemost"},{"key":"2768_CR19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","volume":"8","author":"S Schulman","year":"2010","unstructured":"Schulman S, Anger\u00e5s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8:202\u2013204. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03678.x","journal-title":"J Thromb Haemost"},{"key":"2768_CR20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-x","volume":"49","author":"GW Sun","year":"1996","unstructured":"Sun GW, Shook TL, Kay GL (1996) Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol 49:907\u2013916. https:\/\/doi.org\/10.1016\/0895-4356(96)00025-x","journal-title":"J Clin Epidemiol"},{"key":"2768_CR21","first-page":"1071","volume":"69","author":"FE Harrell","year":"1985","unstructured":"Harrell FE, Lee KL, Matchar DB, Reichert TA (1985) Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 69:1071\u20131077","journal-title":"Cancer Treat Rep"},{"key":"2768_CR22","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/j.jacc.2017.03.600","volume":"69","author":"X Yao","year":"2017","unstructured":"Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA, Non-Vitamin K (2017) Antagonist oral anticoagulant dosing in patients with Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 69:2779\u20132790. https:\/\/doi.org\/10.1016\/j.jacc.2017.03.600","journal-title":"J Am Coll Cardiol"},{"key":"2768_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12603-019-1176-z","volume":"23","author":"E Dent","year":"2019","unstructured":"Dent E, Hoogendijk EO, Visvanathan R, Wright ORL (2019) Malnutrition Screening and Assessment in Hospitalised Older people: a review. J Nutr Health Aging 23:431\u2013441. https:\/\/doi.org\/10.1007\/s12603-019-1176-z","journal-title":"J Nutr Health Aging"},{"key":"2768_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1681\/ASN.2015121308","volume":"28","author":"ED O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan ED, Hughes J, Ferenbach DA (2017) Renal aging: causes and consequences. J Am Soc Nephrol 28:407\u2013420. https:\/\/doi.org\/10.1681\/ASN.2015121308","journal-title":"J Am Soc Nephrol"},{"key":"2768_CR25","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1001\/jama.2017.5706","volume":"317","author":"RM Kok","year":"2017","unstructured":"Kok RM, Reynolds CF 3rd (2017) Management of Depression in older adults: a review. JAMA 317:2114\u20132122. https:\/\/doi.org\/10.1001\/jama.2017.5706","journal-title":"JAMA"},{"key":"2768_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","volume":"7","author":"MA Carlisle","year":"2019","unstructured":"Carlisle MA, Fudim M, DeVore AD, Piccini JP (2019) Heart failure and Atrial Fibrillation, like fire and fury. JACC Heart Fail 7:447\u2013456. https:\/\/doi.org\/10.1016\/j.jchf.2019.03.005","journal-title":"JACC Heart Fail"},{"issue":"2","key":"2768_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/jth.13912","volume":"16","author":"J Douxfils","year":"2018","unstructured":"Douxfils J, Ageno W, Samama CM et al (2018) Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16(2):209\u2013219. https:\/\/doi.org\/10.1111\/jth.13912","journal-title":"J Thromb Haemost"},{"key":"2768_CR28","first-page":"601","volume":"18","author":"C Palleria","year":"2013","unstructured":"Palleria C, Di Paolo A, Giofr\u00e8 C, Caglioti C, Leuzzi G, Siniscalchi A et al (2013) Pharmacokinetic drug-drug interaction and their implication in clinical management. J Res Med Sci 18:601\u2013610","journal-title":"J Res Med Sci"},{"key":"2768_CR29","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s11096-012-9697-0","volume":"34","author":"M Espinosa-Bosch","year":"2012","unstructured":"Espinosa-Bosch M, Santos-Ramos B, Gil-Navarro MV, Santos-Rubio MD, Mar\u00edn-Gil R, Villacorta-Linaza P (2012) Prevalence of drug interactions in hospital healthcare. Int J Clin Pharm 34:807\u2013817. https:\/\/doi.org\/10.1007\/s11096-012-9697-0","journal-title":"Int J Clin Pharm"},{"key":"2768_CR30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/02813430310001806","volume":"21","author":"L Bjerrum","year":"2003","unstructured":"Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21:153\u2013158. https:\/\/doi.org\/10.1080\/02813430310001806","journal-title":"Scand J Prim Health Care"},{"key":"2768_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta S, Corsini A (2018) Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf 17:25\u201337. https:\/\/doi.org\/10.1080\/14740338.2018.1394455","journal-title":"Expert Opin Drug Saf"},{"key":"2768_CR32","first-page":"144","volume":"31","author":"S Williams","year":"2019","unstructured":"Williams S, Miller G, Khoury R, Grossberg GT (2019) Rational deprescribing in the elderly. Ann Clin Psychiatry 31:144\u2013152","journal-title":"Ann Clin Psychiatry"},{"key":"2768_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"2768_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jacc.2021.10.037","volume":"79","author":"AS Volgman","year":"2022","unstructured":"Volgman AS, Nair G, Lyubarova R, Merchant FM, Mason P, Curtis AB et al (2022) Management of Atrial Fibrillation in patients 75 years and older: JACC state-of-the-art review. J Am Coll Cardiol 79:166\u2013179. https:\/\/doi.org\/10.1016\/j.jacc.2021.10.037","journal-title":"J Am Coll Cardiol"},{"key":"2768_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.hrthm.2014.03.006","volume":"11","author":"BA Steinberg","year":"2014","unstructured":"Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, ROCKET AF Steering Committee and Investigators et al (2014) Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm 11:925\u2013932. https:\/\/doi.org\/10.1016\/j.hrthm.2014.03.006","journal-title":"Heart Rhythm"},{"key":"2768_CR36","doi-asserted-by":"publisher","unstructured":"Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, ARISTOTLE Committees and Investigators (2014) Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol 2014;64:1541\u20131550. https:\/\/doi.org\/10.1016\/j.jacc.2014.07.967","DOI":"10.1016\/j.jacc.2014.07.967"},{"key":"2768_CR37","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s11239-020-02037-3","volume":"49","author":"S Hanigan","year":"2020","unstructured":"Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis 49:636\u2013643. https:\/\/doi.org\/10.1007\/s11239-020-02037-3","journal-title":"J Thromb Thrombolysis"},{"key":"2768_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1055\/a-1981-1763","volume":"123","author":"G Foulon-Pinto","year":"2023","unstructured":"Foulon-Pinto G, Lafuente-Lafuente C, Jourdi G, Guen JL, Tall F, Puymirat E et al (2023) Assessment of DOAC in GEriatrics (Adage Study): Rivaroxaban\/Apixaban concentrations and Thrombin Generation profiles in NVAF very Elderly patients. Thromb Haemost 123:402\u2013414. https:\/\/doi.org\/10.1055\/a-1981-1763","journal-title":"Thromb Haemost"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-024-02768-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02768-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T05:11:09Z","timestamp":1716354669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-024-02768-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2768"],"URL":"https:\/\/doi.org\/10.1007\/s40520-024-02768-w","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study methodology corresponds to studies not involving human subjects (MR \u2013 004). The study was conducted in accordance with the Declaration of Helsinki and the database was declared to the French National Commission on Computing and Liberty (CNIL) of the Assistance Publique \u2013 H\u00f4pitaux de Paris (APHP) for this study (n\u00b0 20,230,403,102,132).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for informed consent by individual patients was waived by the CNIL affiliated with the Assistance Publique - H\u00f4pitaux de Paris (AP-HP) given the retrospective nature of the study. Patients that expressed in the medical chart an opposition to the use of their clinical data were excluded from the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"E. Pautas has received honoraria for participating in expert meetings on dabigatran (from Boehringer Ingelheim), rivaroxaban (from Bayer Healthcare AG), apixaban (Bristol Myers Squibb-Pfizer), and warfarin (Merck).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}